CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS
Publication
, Journal Article
Groot, MT; Anstrom, KD; Reed, SD; Uyl-de Groot, CA
Published in: Value in Health
November 2004
Duke Scholars
Published In
Value in Health
DOI
ISSN
1098-3015
Publication Date
November 2004
Volume
7
Issue
6
Start / End Page
644 / 644
Publisher
Elsevier BV
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics
- 1402 Applied Economics
- 1117 Public Health and Health Services
Citation
APA
Chicago
ICMJE
MLA
NLM
Groot, M. T., Anstrom, K. D., Reed, S. D., & Uyl-de Groot, C. A. (2004). CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS. Value in Health, 7(6), 644–644. https://doi.org/10.1016/s1098-3015(10)65656-2
Groot, M. T., K. D. Anstrom, S. D. Reed, and C. A. Uyl-de Groot. “CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS.” Value in Health 7, no. 6 (November 2004): 644–644. https://doi.org/10.1016/s1098-3015(10)65656-2.
Groot MT, Anstrom KD, Reed SD, Uyl-de Groot CA. CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS. Value in Health. 2004 Nov;7(6):644–644.
Groot, M. T., et al. “CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS.” Value in Health, vol. 7, no. 6, Elsevier BV, Nov. 2004, pp. 644–644. Crossref, doi:10.1016/s1098-3015(10)65656-2.
Groot MT, Anstrom KD, Reed SD, Uyl-de Groot CA. CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS. Value in Health. Elsevier BV; 2004 Nov;7(6):644–644.
Published In
Value in Health
DOI
ISSN
1098-3015
Publication Date
November 2004
Volume
7
Issue
6
Start / End Page
644 / 644
Publisher
Elsevier BV
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics
- 1402 Applied Economics
- 1117 Public Health and Health Services